Traditional Chinese medicine composition for treating leukemia
The powder prepared by thistle, dandelion, leukogen and raw traditional Chinese medicine compositions has solved the drug side effects and blood transfusion risks in existing leukemia treatment methods, significantly improved the anemia status of leukemia patients, and achieved effective relief of leukemia and Potential cure.
Patent Information
- Application Number
- CN202411426544.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-12
- Publication Date
- 2024-11-26
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The existing treatment methods for leukemia have drug side effects, blood transfusion risks and treatment dependence, and have failed to fundamentally improve the anemia status, making it difficult to effectively alleviate the anemia symptoms in leukemia patients.
Using thistle, dandelion, leucorrhea root and raw traditional Chinese medicine composition, the preparation of medicinal powder is used for oral treatment, which enhances immunity and improves overall health and alleviates the anemia symptoms of leukemia patients.
Through clinical and mouse experiment verification, the traditional Chinese medicine composition significantly increased the hemoglobin level and red blood cell count of leukemia patients, reduced the symptoms of anemia, and was expected to achieve a complete cure for leukemia.
Smart Images

Figure BDA0005082597770000051
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of traditional Chinese medicine, and in particular to a traditional Chinese medicine composition for treating leukemia. Background Art
[0002] An important test indicator for leukemia patients is their anemia. The main feature of anemia is a decrease in the number of red blood cells in the peripheral blood, which leads to insufficient oxygen supply to tissues and organs. Therefore, effectively solving the anemia problem of patients can inhibit the deterioration of leukemia symptoms and thus achieve effective treatment of leukemia.
[0003] Current treatments for anemia depend on its specific type and cause. Common treatments include dietary modifications, medications, blood transfusions, treatment of underlying causes, surgery, and hematopoietic stem cell transplantation. Dietary modifications focus on increasing the intake of foods rich in iron, folate, and vitamin B12, such as red meat, green leafy vegetables, beans, and nuts. Drug treatments include iron, folate, and vitamin B12 supplements, and erythropoietin. For patients with severe anemia or acute blood loss, blood transfusions can quickly increase hemoglobin levels. In some cases, surgery such as splenectomy is used to treat autoimmune hemolytic anemia, while hematopoietic stem cell transplantation is used to treat certain severe types of anemia.
[0004] Although conventional treatments for anemia are effective, they also have some problems, such as drug side effects, blood transfusion risks, treatment dependence, and unresolved underlying causes. In contrast, traditional Chinese medicine treatments, which have fewer side effects, focus on regulating the functions of internal organs, and can fundamentally improve anemia, have become a better choice for some patients to treat or alleviate anemia. Summary of the invention
[0005] The purpose of the present invention is to provide a method for treating and alleviating anemia in leukemia patients with relatively few side effects and capable of enhancing immunity and improving overall health.
[0006] The Chinese medicine composition for treating leukemia of the present invention comprises the following Chinese herbal medicines in parts by weight:
[0007] 220-260 parts of thistle, 220-260 parts of dandelion, 110-150 parts of Imperata rhizome, and 110-150 parts of Rehmannia glutinosa.
[0008] Preferably, the Chinese medicine composition for treating leukemia comprises the following Chinese herbal medicines in parts by weight:
[0009] 220-255 parts of thistle, 220-250 parts of dandelion, 115-145 parts of Imperata rhizome, and 110-145 parts of Rehmannia glutinosa.
[0010] Preferably, the Chinese medicine composition for treating leukemia comprises the following Chinese herbal medicines in parts by weight:
[0011] 220-255 parts of thistle, 220-250 parts of dandelion, 120-140 parts of Imperata rhizome, and 115-140 parts of Rehmannia glutinosa.
[0012] Preferably, the Chinese medicine composition for treating leukemia comprises the following Chinese herbal medicines in parts by weight:
[0013] 225-250 parts of thistle, 220-250 parts of dandelion, 125-135 parts of Imperata rhizome, and 115-140 parts of Rehmannia glutinosa.
[0014] Preferably, the Chinese medicine composition for treating leukemia comprises the following Chinese herbal medicines in parts by weight:
[0015] 230 parts of thistle, 230 parts of dandelions, 130 parts of Imperata rhizome, and 120 parts of rehmannia root.
[0016] Preferably, the Chinese medicine composition for treating leukemia comprises the following Chinese herbal medicines in parts by weight:
[0017] 245 parts of Thistle, 225 parts of Taraxacum, 125 parts of Imperatae Rhizome, 140 parts of Radix Rehmanniae.
[0018] Preferably, the Chinese medicine composition for treating leukemia comprises the following Chinese herbal medicines in parts by weight:
[0019] 230 parts of thistle, 250 parts of dandelions, 128 parts of Imperata rhizome, and 135 parts of Rehmannia glutinosa.
[0020] Preferably, the Chinese medicine composition for treating leukemia comprises the following Chinese herbal medicines in parts by weight:
[0021] 235 parts of thistle, 235 parts of dandelions, 135 parts of Imperata rhizome, 115 parts of rehmannia root.
[0022] Preferably, the Chinese medicine composition for treating leukemia comprises the following Chinese herbal medicines in parts by weight:
[0023] 240 parts of thistle, 240 parts of dandelions, 125 parts of Imperata rhizome, 140 parts of rehmannia root.
[0024] Preferably, the Chinese medicine composition for treating leukemia comprises the following Chinese herbal medicines in parts by weight:
[0025] 250 parts of thistle, 220 parts of dandelions, 130 parts of Imperata rhizome, and 130 parts of Rehmannia glutinosa.
[0026] Compared with the prior art, the beneficial technical effects of the present invention are:
[0027] The Chinese medicine composition of the present invention is prepared by combining thistle, dandelion, Imperata root and Radix Rehmanniae. After a large number of clinical and mouse experiments, the Chinese medicine composition of the present invention is used to treat leukemia patients, thereby effectively alleviating the anemia symptoms of leukemia patients, and is expected to achieve a complete cure for leukemia. DETAILED DESCRIPTION
[0028] In order to make the purpose, technical scheme and advantages of the present invention clearer, the preferred embodiments of the present invention are further described in detail in conjunction with the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0029] Example 1
[0030] A Chinese medicine composition for treating leukemia, prepared from the following Chinese herbal medicines in parts by weight:
[0031] 230 parts of thistle, 230 parts of dandelions, 130 parts of Imperata rhizome, and 120 parts of rehmannia root.
[0032] Example 2
[0033] A Chinese medicine composition for treating leukemia, prepared from the following Chinese herbal medicines in parts by weight:
[0034] 245 parts of Thistle, 225 parts of Taraxacum, 125 parts of Imperatae Rhizome, 140 parts of Radix Rehmanniae.
[0035] Example 3
[0036] A Chinese medicine composition for treating leukemia, prepared from the following Chinese herbal medicines in parts by weight:
[0037] 230 parts of thistle, 250 parts of dandelions, 128 parts of Imperata rhizome, and 135 parts of Rehmannia glutinosa.
[0038] Example 4
[0039] A Chinese medicine composition for treating leukemia, prepared from the following Chinese herbal medicines in parts by weight:
[0040] 235 parts of thistle, 235 parts of dandelions, 135 parts of Imperata rhizome, 115 parts of rehmannia root.
[0041] Example 5
[0042] A Chinese medicine composition for treating leukemia, prepared from the following Chinese herbal medicines in parts by weight:
[0043] 240 parts of thistle, 240 parts of dandelions, 125 parts of Imperata rhizome, 140 parts of rehmannia root.
[0044] Example 6
[0045] 250 parts of thistle, 220 parts of dandelions, 130 parts of Imperata rhizome, and 130 parts of Rehmannia glutinosa.
[0046] Example 7
[0047] A Chinese medicine composition for treating leukemia, prepared from the following Chinese herbal medicines in parts by weight:
[0048] 220 parts of thistle, 220 parts of dandelions, 110 parts of Imperata rhizome, 110 parts of rehmannia root.
[0049] Example 8
[0050] A Chinese medicine composition for treating leukemia, prepared from the following Chinese herbal medicines in parts by weight:
[0051] 260 parts of Thistle, 260 parts of Taraxacum, 150 parts of Imperatae Rhizome, 150 parts of Radix Rehmanniae.
[0052] The Chinese medicine compositions prepared in Examples 1 to 8 were crushed and decocted in water for 2 hours, concentrated and freeze-dried to obtain medicine powders.
[0053] The prepared powder was taken orally by random leukemia patients at a dosage of 0.1 g / time, three times a day. After taking the powder for three months, the symptoms of the leukemia patients were tested, and the results showed that the symptoms were alleviated to varying degrees.
[0054] The powders prepared in Example 1, Example 3 and Example 6 (powder #1, powder #2 and powder #3) were tested on anemic mice. The specific testing method is as follows:
[0055] 100 male SPF Kunming mice weighing 18-20 g were used. They were adaptively fed for 7 days and randomly divided into 10 groups, 10 mice in each group, namely normal group, model group, 1# experimental group, 2# experimental group, and 3# experimental group. Except for the normal group, the other groups were intraperitoneally injected with 10 mg kg -1 Busulfan solution: intraperitoneal injection of 20 mg kg on d 2, 4, 6, 8, 10, and 12 -1 Cyclophosphamide was used to prepare aplastic anemia mouse model. Each group was intragastrically administered with a set dose (20 mL kg -1 ), once a day for 30 days, and the normal group and model group were given an equal amount of distilled water. After the last administration, the subjects were fasted but not watered for 12 hours, and then samples were taken for determination of hemoglobin (Hb) content, red blood cell (RBC) and white blood cell (WBC) counts. The test results are shown in Table 2.
[0056] Unless otherwise specified, all experiments were repeated three times. SPSS 21.0 was used for analysis of variance (ANOVA) and Duncan's multiple comparison analysis, and the results were expressed as mean ± SD.
[0057] Table 2
[0058]
[0059]
[0060] Note: Compared with the normal group, *P<0.05, **P<0.01; compared with the model group, #P<0.05, ##P<0.01.
[0061] Test Example 2
[0062] A total of 100 male SPF Kunming mice weighing 18-20 g were used. They were adaptively fed for 7 days and randomly divided into 10 groups, with 10 mice in each group, namely the normal group, model group, 1# experimental group, 2# experimental group, and 3# experimental group.
[0063] Except for the normal group, the other groups were fed with iron-deficient feed. After feeding for 30 days, the hemoglobin (Hb) content and red blood cell count (RBC) of the mice were detected. The test results are shown in Table 3.
[0064] Unless otherwise specified, all experiments were repeated three times. SPSS 21.0 was used for analysis of variance (ANOVA) and Duncan's multiple comparison analysis, and the results were expressed as mean ± SD.
[0065] Table 3
[0066] deal with <![CDATA[RBC(×10 12 ·L -1 )]]> <![CDATA[HGB(g·L -1 )]]> Normal group 9.26±0.34 140.55±5.24 Model Group <![CDATA[6.67±0.57 ** ]]> <![CDATA[104.01±4.67 ** ]]> 1# Experimental group <![CDATA[8.47±0.12 ## ]]> <![CDATA[127.62±5.32 ## ]]> 2# Experimental Group <![CDATA[8.40±0.38 ## ]]> <![CDATA[126.64±2.67 ## ]]> 3# Experimental group <![CDATA[8.54±0.76 ## ]]> <![CDATA[128.46±2.29 ## ]]>
[0067] Note: Compared with the normal group, *P<0.05, **P<0.01; compared with the model group, #P<0.05, ##P<0.01.
[0068] The embodiments described above are part of the embodiments of the present invention, rather than all of the embodiments. The detailed description of the embodiments of the present invention is not intended to limit the scope of the invention claimed for protection, but merely represents selected embodiments of the present invention. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
Claims
1. A Chinese medicine composition for treating leukemia, characterized in that: The invention comprises the following Chinese herbal medicines in parts by weight: 220-260 parts of thistle, 220-260 parts of dandelion, 110-150 parts of Imperata rhizome, and 110-150 parts of Rehmannia glutinosa.
2. The Chinese medicine composition for treating leukemia according to claim 1, characterized in that: The invention comprises the following Chinese herbal medicines in parts by weight: 220-255 parts of thistle, 220-255 parts of dandelion, 110-145 parts of Imperata rhizome, and 110-145 parts of Rehmannia glutinosa.
3. The Chinese medicine composition for treating leukemia according to claim 1, characterized in that: The invention comprises the following Chinese herbal medicines in parts by weight: 220-255 parts of thistle, 220-255 parts of dandelion, 115-140 parts of Imperata rhizome, and 115-140 parts of Rehmannia glutinosa.
4. The Chinese medicine composition for treating leukemia according to claim 1, characterized in that: The invention comprises the following Chinese herbal medicines in parts by weight: 225-250 parts of thistle, 225-250 parts of dandelion, 115-140 parts of Imperata rhizome, and 115-140 parts of Rehmannia glutinosa.
5. The Chinese medicine composition for treating leukemia according to claim 1, characterized in that: The invention comprises the following Chinese herbal medicines in parts by weight: 230 parts of thistle, 230 parts of dandelions, 130 parts of Imperata rhizome, and 120 parts of rehmannia root.
6. The Chinese medicine composition for treating leukemia according to claim 1, characterized in that: The invention comprises the following Chinese herbal medicines in parts by weight: 245 parts of Thistle, 225 parts of Taraxacum, 125 parts of Imperatae Rhizome, 140 parts of Radix Rehmanniae.
7. The Chinese medicine composition for treating leukemia according to claim 1, characterized in that: The invention comprises the following Chinese herbal medicines in parts by weight: 230 parts of thistle, 250 parts of dandelions, 128 parts of Imperata rhizome, and 135 parts of Rehmannia glutinosa.
8. The Chinese medicine composition for treating leukemia according to claim 1, characterized in that: The invention comprises the following Chinese herbal medicines in parts by weight: 235 parts of thistle, 235 parts of dandelions, 135 parts of Imperata rhizome, 115 parts of rehmannia root.
9. The Chinese medicine composition for treating leukemia according to claim 1, characterized in that: The invention comprises the following Chinese herbal medicines in parts by weight: 240 parts of thistle, 240 parts of dandelions, 125 parts of Imperata rhizome, 140 parts of rehmannia root.
10. The Chinese medicine composition for treating leukemia according to claim 1, characterized in that: The invention comprises the following Chinese herbal medicines in parts by weight: 250 parts of thistle, 220 parts of dandelions, 130 parts of Imperata rhizome, and 130 parts of Rehmannia glutinosa.
Citation Information
Patent Citations
Chinese patent medicine for treating acute leukemia and preparation method thereof
CN115068562A
Chinese patent medicine for curing acute leukemia and its preparation process
CN1303708A
